Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients

Fig. 1

The comparisons of COMPASS-31 score/subscore among NMOSD subgroups, only displaying the significantly different results (P < 0.05). The detailed results of the comparisons of COMPASS-31 score/subscore among NMOSD subgroups distributed by gender, AQP4 seropositivity or seronegativity, clinical phenotype, and current preventive therapy could be seen in Supplementary Table S1. COMPASS-31, Composite Autonomic Symptom Score 31. ON, optica neuritis; TM, transverse myelitis; MMF, mycophenolate mofetil; AZA, azathioprine; RTX, rituximab

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us